[FGEN] FibroGen, Inc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 20.8 Change: 1.3 (6.67%)
Ext. hours: Change: 0 (0%)

chart FGEN

Refresh chart

Strongest Trends Summary For FGEN

FGEN is in the medium-term down -26% below S&P in 1 year and down -42% below S&P in 2 years. In the long-term up 21% in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: FibroGen, Inc. discovers, develops, and commercializes drugs for anemia and pulmonary fibrosis. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was founded in 1993 and is headquartered in San Francisco, California.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 19.29% Sales Growth - Q/Q1.2% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-31.33% ROE-73.92% ROI-45.95%
Current Ratio2.88 Quick Ratio Long Term Debt/Equity0.95 Debt Ratio0.29
Gross Margin Operating Margin-281.76% Net Profit Margin-296.24% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities620 K Cash From Investing Activities4.55 M Cash From Operating Activities-42.19 M Gross Profit
Net Profit-46.37 M Operating Profit-44.72 M Total Assets435.54 M Total Current Assets155.4 M
Total Current Liabilities53.96 M Total Debt111.65 M Total Liabilities250.92 M Total Revenue16.3 M
Technical Data
High 52 week60.16 Low 52 week35.13 Last close38.86 Last change2.18%
RSI54.39 Average true range1.65 Beta1.52 Volume241.17 K
Simple moving average 20 days2.88% Simple moving average 50 days-5.87% Simple moving average 200 days-16.81%
Performance Data
Performance Week6.91% Performance Month-7.08% Performance Quart-15.89% Performance Half-19.09%
Performance Year-21.89% Performance Year-to-date-16.03% Volatility daily2.23% Volatility weekly4.98%
Volatility monthly10.21% Volatility yearly35.38% Relative Volume223.58% Average Volume567.87 K
New High New Low

News

2020-05-27 07:00:10 | FibroGen to Present at Upcoming Investor Conferences

2020-05-21 07:00:10 | European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Roxadustat

2020-05-20 22:00:00 | European Medicines Agency Accepts Astellas' Marketing Authorization Application for Roxadustat

2020-05-11 06:32:09 | FibroGen, Inc. NASDAQ:FGEN Analysts Are Cutting Their Estimates: Here's What You Need To Know

2020-05-09 17:01:59 | FibroGen Inc FGEN Q1 2020 Earnings Call Transcript

2020-05-08 19:24:35 | Edited Transcript of FGEN earnings conference call or presentation 7-May-20 9:00pm GMT

2020-05-08 07:00:10 | FibroGen to Present at Bank of America Securities 2020 Health Care Conference

2020-05-07 20:40:12 | FibroGen FGEN Reports Q1 Loss, Lags Revenue Estimates

2020-05-07 16:01:10 | FibroGen Reports First Quarter 2020 Financial Results

2020-05-07 11:24:25 | Akebia Shares Climb on Positive Anemia Drug Study Results

2020-05-06 08:43:12 | Why FibroGen FGEN Might Surprise This Earnings Season

2020-05-03 10:17:04 | How Does Investing In FibroGen, Inc. NASDAQ:FGEN Impact The Volatility Of Your Portfolio?

2020-04-30 12:33:04 | FibroGen FGEN Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

2020-04-24 07:00:10 | FibroGen To Report First Quarter 2020 Financial Results

2020-04-21 17:31:13 | Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO

2020-04-20 07:00:10 | FibroGen Reports UK Court Ruling

2020-03-27 14:52:43 | Hedge Funds Were Selling FibroGen Inc FGEN Before The Coronavirus

2020-03-04 07:07:09 | Here's What Analysts Are Forecasting For FibroGen, Inc. After Its Full-Year Results

2020-03-03 20:13:12 | Edited Transcript of FGEN earnings conference call or presentation 2-Mar-20 10:00pm GMT

2020-03-03 17:50:48 | After coronavirus shutdown, S.F. drugmaker reopens China plants in time for major product push

2020-03-02 17:15:10 | FibroGen FGEN Reports Q4 Loss, Lags Revenue Estimates

2020-03-02 16:01:10 | FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results

2020-02-24 12:30:05 | Analysts Estimate FibroGen FGEN to Report a Decline in Earnings: What to Look Out for

2020-02-18 07:00:10 | FibroGen to Report Fourth Quarter and Full Year 2019 Financial Results

2020-02-12 09:45:02 | FibroGen's FGEN NDA for Roxadustat Accepted by the FDA

2020-02-12 09:18:32 | The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

2020-02-11 17:00:10 | FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease

2020-02-11 08:00:10 | FibroGen to Present at 9th Annual SVB Leerink Global Healthcare Conference

2020-02-03 15:42:57 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of FibroGen, Inc. - FGEN

2020-01-31 09:12:01 | FibroGen NASDAQ:FGEN Has A Pretty Healthy Balance Sheet

2020-01-30 00:01:00 | Astellas Submits Supplemental New Drug Application for Approval of Evrenzo® roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan

2020-01-13 17:59:36 | 2019 Review: Top Hedge Fund Stocks vs. FibroGen Inc FGEN

2020-01-06 18:03:24 | Four months after CEO's death, biotech company names Lilly vet as leader

2020-01-06 18:03:24 | Four months after CEO's death, biotech company names Lilly vet as leader

2020-01-06 07:00:10 | FibroGen Names Enrique Conterno as Chief Executive Officer

2019-12-24 08:55:01 | Are Options Traders Betting on a Big Move in FibroGen FGEN Stock?

2019-12-23 17:42:29 | Hemophilia gene therapy leads Bay Area trio of year-end FDA approval requests

2019-12-23 17:42:29 | Hepatitis gene therapy leads Bay Area trio of year-end FDA approval requests

2019-12-23 07:00:10 | FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease

2019-12-17 06:45:51 | Is FibroGen's NASDAQ:FGEN 136% Share Price Increase Well Justified?

2019-12-06 10:03:53 | Hedge Funds Have Never Been This Bullish On FibroGen Inc FGEN

2019-12-02 07:00:10 | FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List

2019-11-15 14:20:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN

2019-11-14 19:42:00 | FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm

2019-11-14 17:24:26 | Edited Transcript of FGEN earnings conference call or presentation 11-Nov-19 10:00pm GMT

2019-11-13 20:03:00 | HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen FGEN Investors to Contact Its Attorneys, Firm Investigating Possible Securities Fraud

2019-11-13 19:00:00 | Glancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors

2019-11-13 18:19:00 | INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. Investors

2019-11-13 14:00:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN

2019-11-11 17:15:10 | FibroGen FGEN Reports Q3 Loss, Tops Revenue Estimates